Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Scott

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|March 13, 2016
Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapiesAlexandra Belson, Tim Schmidt, Disala Fernando, et al.
Current Alzheimer Research|March 26, 2013
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigationPradeep J Nathan, Rebecca Boardley, Nicola Scott, et al.
European Journal of Pediatrics|February 17, 2024
Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension studyDunbar Ivy, Maurice Beghetti, Ernesto Juaneda-Simian, et al.
Clinical Pharmacology and Therapeutics|April 18, 2020
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled StudyKathleen Weisel, Scott Berger, Kim Papp, et al.
Australian and New Zealand Journal of Public Health|May 27, 2026
Nurse-led virtual triage is cost effective for bowel cancer screening referrals for colonoscopy: An economic evaluation of direct access colonoscopy in New South WalesSarah Gerritsen, Martin Howell, Winnie Chen, et al.
Regenerative Medicine|May 31, 2022
Growth factors: avenues for the treatment of myocardial infarction and potential delivery strategiesDemin Li, Kang Tian, Jiacheng Guo, et al.
BMJ Open Gastroenterology|August 14, 2021
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitisKathy Weisel, Nicola Scott, Scott Berger, et al.
Ebiomedicine|June 10, 2026
Implementing portable, real-time 16S rRNA sequencing in the healthcare sector enhances antimicrobial stewardshipEdward Cunningham-Oakes, David Carlisle, June Booth, et al.
JAMA|March 14, 2022
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
The New England Journal of Medicine|October 27, 2021
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody SotrovimabAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|March 13, 2016
Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapiesAlexandra Belson, Tim Schmidt, Disala Fernando, et al.
Current Alzheimer Research|March 26, 2013
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigationPradeep J Nathan, Rebecca Boardley, Nicola Scott, et al.
European Journal of Pediatrics|February 17, 2024
Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension studyDunbar Ivy, Maurice Beghetti, Ernesto Juaneda-Simian, et al.
Clinical Pharmacology and Therapeutics|April 18, 2020
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled StudyKathleen Weisel, Scott Berger, Kim Papp, et al.
Australian and New Zealand Journal of Public Health|May 27, 2026
Nurse-led virtual triage is cost effective for bowel cancer screening referrals for colonoscopy: An economic evaluation of direct access colonoscopy in New South WalesSarah Gerritsen, Martin Howell, Winnie Chen, et al.
Regenerative Medicine|May 31, 2022
Growth factors: avenues for the treatment of myocardial infarction and potential delivery strategiesDemin Li, Kang Tian, Jiacheng Guo, et al.
BMJ Open Gastroenterology|August 14, 2021
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitisKathy Weisel, Nicola Scott, Scott Berger, et al.
Ebiomedicine|June 10, 2026
Implementing portable, real-time 16S rRNA sequencing in the healthcare sector enhances antimicrobial stewardshipEdward Cunningham-Oakes, David Carlisle, June Booth, et al.
JAMA|March 14, 2022
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
The New England Journal of Medicine|October 27, 2021
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody SotrovimabAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.
Pageof 3